Enbrel Psoriatic Arthritis Indication Added To Medicare Part B Demo
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services has added coverage of Wyeth/Amgen's Enbrel (etanercept) for psoriatic arthritis to its Part B demonstration project
You may also be interested in...
Remicade Helped By “Slow Start” To Medicare Part B Demo
Johnson & Johnson's rheumatoid arthritis therapy Remicade is feeling virtually no impact from a Medicare demonstration project that provides coverage to competing agents, Group Chairman-Biopharmaceuticals Joe Scodari said during the Bear Stearns health care conference in New York Sept. 13
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.